NO20053237L - Azapeptider. - Google Patents

Azapeptider.

Info

Publication number
NO20053237L
NO20053237L NO20053237A NO20053237A NO20053237L NO 20053237 L NO20053237 L NO 20053237L NO 20053237 A NO20053237 A NO 20053237A NO 20053237 A NO20053237 A NO 20053237A NO 20053237 L NO20053237 L NO 20053237L
Authority
NO
Norway
Prior art keywords
dementia
azapeptide
pugihstica
hehwa
azaaminoic
Prior art date
Application number
NO20053237A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053237D0 (no
Inventor
Claudio Soto-Jara
Thomas Rueckle
John Jairo Lopez Areiza
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20053237D0 publication Critical patent/NO20053237D0/no
Publication of NO20053237L publication Critical patent/NO20053237L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20053237A 2002-12-02 2005-07-01 Azapeptider. NO20053237L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02102673 2002-12-02
PCT/EP2003/015033 WO2004050689A2 (fr) 2002-12-02 2003-12-01 Azapeptides

Publications (2)

Publication Number Publication Date
NO20053237D0 NO20053237D0 (no) 2005-07-01
NO20053237L true NO20053237L (no) 2005-07-01

Family

ID=32405771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053237A NO20053237L (no) 2002-12-02 2005-07-01 Azapeptider.

Country Status (8)

Country Link
US (1) US20060281686A1 (fr)
EP (1) EP1567546A2 (fr)
JP (1) JP2006520321A (fr)
AR (1) AR042258A1 (fr)
AU (1) AU2003298260A1 (fr)
CA (1) CA2505150A1 (fr)
NO (1) NO20053237L (fr)
WO (1) WO2004050689A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472563B (en) * 2009-04-28 2013-02-27 Univ Leicester Method of preparing hairpin and cyclic polyamides
WO2020227592A1 (fr) * 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Thiosemicarbazates et leurs utilisations
IL287499B2 (en) 2019-05-09 2025-11-01 Feinstein Institutes For Medical Research Compounds for use in synthesis of peptidomimetics
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
EP3965792A4 (fr) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research Antagoniste de hmgb1
US20200354404A1 (en) * 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Peptidomimetic agents, synthesis and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1081809B (it) * 1977-06-07 1985-05-21 Isf Spa Idrazono cefalosporine
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof

Also Published As

Publication number Publication date
AU2003298260A1 (en) 2004-06-23
AR042258A1 (es) 2005-06-15
EP1567546A2 (fr) 2005-08-31
US20060281686A1 (en) 2006-12-14
WO2004050689A3 (fr) 2004-09-30
NO20053237D0 (no) 2005-07-01
CA2505150A1 (fr) 2004-06-17
JP2006520321A (ja) 2006-09-07
WO2004050689A2 (fr) 2004-06-17

Similar Documents

Publication Publication Date Title
KR960704839A (ko) β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production)
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
DE60216122D1 (de) Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2000072876A3 (fr) Prevention et traitement de maladies amyloidogenes
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
WO2002088101A3 (fr) Inhibiteurs de bace
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
NO20053237L (no) Azapeptider.
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
GEP20063869B (en) Novel cyclohexyl sulphones
WO2007021886A3 (fr) Compositions de memapsine 2 tronquee et traitements associes
WO1999041279A3 (fr) Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque
WO2004096845A3 (fr) Inhibiteurs de beta-amyloide et leur utilisation
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
WO1999058098A8 (fr) Antithrombines iii humaines et procedes connexes
WO2004005336A3 (fr) Peptides de rupture de feuillets $g(b)
WO2002099061A3 (fr) Procedes et compositions pour traiter des maladies associees aux aberrations dans la transduction de signaux
WO2002070537A3 (fr) Derives d'acide fusidique
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
PL355113A1 (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application